Special Situations, Content Strategist, Smartkarma

Crispin Francis

Special Situations, Content Strategist

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Event-Driven

On 10 April 2017, <a href="https://www.smartkarma.com/entities/21706" target="_blank" data-smartkarma-citation="entities:21706:1">STADA Arzneimittel AG (SAZ GR)</a>'s executive board announced that it was supporting a EUR 66 offer (EUR 65.28 + 0.72 in divs) from Bain Capital &amp; Cinven (the "Consortium"). This came after a bidding process involving PE firms Advent, CVC and Bain + Cinven.Bain Capital + Cinven emerged as the winner bidders following thorough talks with interested parties and after an open, multistage and transparently structured bidding process. In this insight, we take a look at the transaction and give our opinion on the likelihood of a successful deal.

On 10 April 2017, STADA Arzneimittel AG (SAZ GR)'s executive board announced that it was supporting a EUR 66 offer (EUR 65.28 + 0.72 in divs) from Bain Capital &amp; Cinven (the "Consortium"). This came after a bidding process involving PE firms Advent, CVC and Bain + Cinven.Bain Capital + Cinven emerged as the winner bidders following thorough talks with interested parties and after an open, multistage and transparently structured bidding process. In this insight, we take a look at the transaction and give our opinion on the likelihood of a successful deal. 

STADA - Bain+Cinven Emerge as the Winning Bidders